190 related articles for article (PubMed ID: 9191002)
21. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases.
Menon S; Deodhar K; Rekhi B; Dhake R; Gupta S; Ghosh J; Maheshwari A; Mahantshetty U; Shrivastva S; Budukh A; Tongaonkar HB; Kerkar R
Indian J Pathol Microbiol; 2013; 56(4):365-71. PubMed ID: 24441223
[TBL] [Abstract][Full Text] [Related]
22. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
23. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.
Gamallo C; Palacios J; Moreno G; Calvo de Mora J; Suárez A; Armas A
Am J Pathol; 1999 Aug; 155(2):527-36. PubMed ID: 10433945
[TBL] [Abstract][Full Text] [Related]
24. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
25. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
26. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
Shigemasa K; Katoh O; Shiroyama Y; Mihara S; Mukai K; Nagai N; Ohama K
Jpn J Cancer Res; 2002 May; 93(5):542-50. PubMed ID: 12036450
[TBL] [Abstract][Full Text] [Related]
27. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
28. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas.
Shigemasa K; Shiroyama Y; Sawasaki T; Fujii T; Nagai N; Parmley TH; O'Brien TJ; Ohama K
Int J Oncol; 2001 May; 18(5):953-8. PubMed ID: 11295040
[TBL] [Abstract][Full Text] [Related]
29. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
30. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
31. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
32. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
33. Fatty acid synthesis: a potential selective target for antineoplastic therapy.
Kuhajda FP; Jenner K; Wood FD; Hennigar RA; Jacobs LB; Dick JD; Pasternack GR
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6379-83. PubMed ID: 8022791
[TBL] [Abstract][Full Text] [Related]
34. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
35. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
36. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.
Kristiansen G; Denkert C; Schlüns K; Dahl E; Pilarsky C; Hauptmann S
Am J Pathol; 2002 Oct; 161(4):1215-21. PubMed ID: 12368195
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma.
Sebastiani V; Visca P; Botti C; Santeusanio G; Galati GM; Piccini V; Capezzone de Joannon B; Di Tondo U; Alo PL
Gynecol Oncol; 2004 Jan; 92(1):101-5. PubMed ID: 14751145
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma.
Nemoto T; Terashima S; Kogure M; Hoshino Y; Kusakabe T; Suzuki T; Gotoh M
Pathobiology; 2001; 69(6):297-303. PubMed ID: 12324706
[TBL] [Abstract][Full Text] [Related]
40. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
Huang W; Cheng X; Ji J; Zhang J; Li Q
Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
